CD4 and cancer: Thus, patients with advanced cancer had elevated levels of activation markers involved in immune checkpoint pathways in both CD4+ and CD8+ T cells, higher Tregs and MDSCs with a suppressive phenotype, and differences in PD-L1 expression on antigen-presenting cells (APCs) compared to age-matched healthy donors.